Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP)

Phase 2 Active not recruiting 62 enrolled Keymed Biosciences Co.Ltd

RandomizedSequentialQuadruple-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and initial efficacy of CM313 (SC) injection in patients with primary immune thrombocytopenia.

Timeline

Start: 2024-11-11
Primary completion: 2025-12-30
Completion: 2025-12-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LUMROTATUG	Monoclonal antibody	—	Subcutaneous

Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP)

Summary

Timeline

Drugs

Indications